RxDoctor Payments Data

Adel Yaacoub, MD

Cardiovascular Disease · Lafayette, INNPI 1477572550

Payments from drug & device makers

$4,108in general payments, 2019–2025

Across 128 payments — averaging $32.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Research Incorporated$1K
  • Abiomed$473
  • Johnson & Johnson$409
  • E.r. Squibb & Sons, L.L.C.$376
  • Novartis$253
  • Amgen$236
  • plus $1K from 24 others

What the payments were for

  • Consulting fees$1,10327%
  • Travel & lodging$3128%
  • Food & beverage$2,69366%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,108 in reported general payments places this provider in the 55th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$70,293
Medicare patients
339
Services billed
853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$59,495
BrilintaTicagrelor64$36,234
EntrestoSacubitril/Valsartan20$11,844
Repatha SureclickEvolocumab15$9,438
XareltoRivaroxaban14$8,638
Amiodarone Hcl71$1,446
Metoprolol Succinate123$1,228
Nifedipine ErNifedipine16$738
Rosuvastatin Calcium38$549
Cilostazol36$522
Nitroglycerin60$369
Atorvastatin Calcium66$367
Chlorthalidone33$366
ClopidogrelClopidogrel Bisulfate66$362
Amlodipine Besylate63$289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$163$59,49569 claims
AstraZenecaBrilinta$95$36,23464 claims
NovartisEntresto$253$11,84420 claims
Johnson & JohnsonXarelto$409$8,63814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Lafayette

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →